摘要:
A system evaluates the performance of an implantable medical device, such as by using a remote external server and a user interface and stored historical physiological data of a population of congestive heart failure (CHF) patients. A processor is coupled to a patient data storage device to apply multiple algorithm variations against the same implantable physiological data from the patient to produce corresponding resulting CHF indicators. The user interface includes a display that is configured to display to a user information allowing comparison between the resulting CHF indicators from the multiple algorithm variations. The display also includes a population data selector to permit the user to select physiological data from a population that includes a different set of one or more patients or physiological data collected over a period of time from the patient. This permits optimization of an algorithm parameter or selection of a best performing algorithm.
摘要:
An implantable cardioverter/defibrillator (ICD) includes a tachyarrhythmia detection and classification system that classifies tachyarrhythmias based on a morphological analysis of arrhythmic waveforms and a template waveform. Correlation coefficients each computed between morphological features of an arrhythmic waveform and morphological features of the template waveform provide for the basis for classifying the tachyarrhythmia. In one embodiment, a correlation analysis takes into account the uncertainty associated with the production of the template waveform by using a template band that includes confidence intervals.
摘要:
A system including at least one implantable sensor circuit adapted to produce an electrical sensor signal related to one or more physiologic cardiovascular events of a subject, a therapy circuit configured to provide anti-tachycardia pacing (ATP) therapy, and a controller. The controller includes a tachyarrhythmia detection circuit and an efficacy circuit. The tachyarrhythmia detection circuit is configured to detect a tachyarrhythmia episode in the subject using the electrical sensor signal, and to determine whether the tachyarrhythmia episode is of a type that is treatable with ATP. The efficacy circuit is configured to estimate an efficacy of a currently configured ATP therapy for the subject, and the controller is configured to alter a delivery regimen of the currently configured ATP therapy when the estimated ATP therapy efficacy is deemed insufficient. Other systems and methods are described.
摘要:
An implantable cardioverter/defibrillator (ICD) delivers atrial pacing under several scenarios during a tachyarrhythmia episode that is detected using a ventricular rate. In various embodiments, the atrial pacing terminates the detected tachyarrhythmia and/or enhances the classification of the detected tachyarrhythmia, thus avoiding ineffective and/or unnecessary delivery of a ventricular anti-tachyarrhythmia therapy when the detected tachyarrhythmia has a supraventricular origin.
摘要:
A cardiac rhythm management (CRM) system delivers anti-tachyarrhythmia therapies and uses patient-specific and/or tachyarrhythmia event-specific information to automatically set and adjust one or more arrhythmia detection durations. In one embodiment, the CRM system initializes and updates the one or more arrhythmia detection durations using patient-specific information such as medical history and recent medical trends. In another embodiment, the CRM dynamically adjusts the one or more arrhythmia detection durations using the patient's hemodynamic performance. One example of such an arrhythmia detection duration is a sustained rate duration (SRD) that starts when a tachyarrhythmia such as a supraventricular tachyarrhythmia is detected. An anti-tachyarrhythmia therapy is delivered only if the tachyarrhythmia sustains throughout the SRD.
摘要:
A system comprising a medical device including a processor and a Z-score transformation (ZST) module. The system also includes a display in communication with the processor. The processor is adapted to receive sensor data obtained from at least first and second sensors adapted to produce a time-varying physiologic electrical sensor signal. At least one of the first and second sensors is implantable. The ZST module calculates a ZST for the sensor data received from the first sensor and a ZST for the sensor data received from the second sensor. The display is adapted to display the ZSTs in visual correspondence with each other over time.
摘要:
A system comprising an implantable medical device (IMD) that includes a tachyarrhythmia detector, a baroreflex detector to obtain baroreflex information, and a processor in communication with the tachyarrhythmia detector and the baroreflex detector. The processor adjusts at least one of a tachyarrhythmia detection parameter of the IMD or a tachyarrhythmia therapy parameter of the IMD using the baroreflex information.
摘要:
Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.
摘要翻译:公开了具有SEQ ID NO:2的氨基酸序列并且具有SEQ ID NO:2的氨基酸残基9至27的多肽,它们共同命名为CKLF1的C末端多肽。 还公开了含有治疗有效量的CKLF1 C末端多肽和药学上可接受的盐,载体或赋形剂的药物组合物。 还公开了编码CKLF1的C末端多肽的多核苷酸,以及含有多核苷酸的载体和宿主细胞; 用于检测测试样品中多肽或多核苷酸的表达水平的体外测定; 以及针对多肽或其活性片段的单克隆或多克隆抗体。 本发明的多肽可以用于治疗HIV感染,过敏性疾病,同种异体移植排斥,脑部疾病和自身免疫性疾病。